Marilyn L Mootz1, Rachel S Britt1,2, Allison A Mootz3, Grace C Lee1,2, Kelly R Reveles1,2, Kirk E Evoy1,2,4, Chengwen Teng1,2, Christopher R Frei1,2,4,5. 1. College of Pharmacy, The University of Texas at Austin, Austin, TX, USA. 2. Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 3. Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA. 4. Pharmacy Service, University Health System, San Antonio, TX, USA. 5. Research and Development Service, South Texas Veterans Health Care System, San Antonio, TX, USA.
Abstract
Objectives: This study compared hospital readmission and mortality for patients with sepsis who received ceftaroline or daptomycin as first-line MRSA therapy. Methods: This retrospective comparative-effectiveness study included adults ≥18 years old hospitalized in the United States Veterans Health Care System with sepsis between 10/1/2010-9/30/2014, who received ceftaroline or daptomycin within 14 days of hospital admission as the first antibiotic effective against methicillin resistant Staphylococcus aureus (MRSA). Patients with pneumonia, and those who received both study drugs, were excluded. Baseline characteristics were compared using Chi-square, Fischer's exact, Student's t, and Wilcoxon Rank Sum tests. Patient outcomes were compared with multivariable logistic regression models. Results: 409 patients were included (ceftaroline = 67, daptomycin = 342). Ceftaroline patients were older, less likely to be Black, more likely to have diabetes with complications, and had higher Charlson comorbidity scores. Median (interquartile range) time from admission to drug initiation was 1 (0-1) day for ceftaroline and 1 (1-3) day for daptomycin (p = 0.01). Unadjusted hospital readmission rates for ceftaroline and daptomycin, respectively, were: 30-day (25%/37%, p = 0.06), 60-day (27%/44%, p = 0.008), and 90-day (28%/46%, p = 0.01). Unadjusted mortality rates were: in-hospital (7%/12%, p = 0.4), 30-day (3%/9%, p = 0.1), 60-day (6%/12%, p = 0.2), and 90-day (7%/15%, p = 0.1). In multivariable models with all divergent baseline characteristics included as covariates, patients treated with ceftaroline were less likely to experience (OR, 95% CI): 30/60/90-day hospital readmission (0.54, 0.29-0.98; 0.42, 0.23-0.76; 0.42, 0.23-0.75) and 30/60/90-day mortality (0.23, 0.04-0.82; 0.34, 0.10-0.93; 0.34, 0.11-0.86). Conclusion: In patients with sepsis, ceftaroline was associated with fewer hospital readmissions and lower mortality as compared to daptomycin. Prospective investigations in larger, more generalized cohorts are needed to examine outcomes with specific MRSA therapies.
Objectives: This study compared hospital readmission and mortality for patients with sepsis who received ceftaroline or daptomycin as first-line MRSA therapy. Methods: This retrospective comparative-effectiveness study included adults ≥18 years old hospitalized in the United States Veterans Health Care System with sepsis between 10/1/2010-9/30/2014, who received ceftaroline or daptomycin within 14 days of hospital admission as the first antibiotic effective against methicillin resistant Staphylococcus aureus (MRSA). Patients with pneumonia, and those who received both study drugs, were excluded. Baseline characteristics were compared using Chi-square, Fischer's exact, Student's t, and Wilcoxon Rank Sum tests. Patient outcomes were compared with multivariable logistic regression models. Results: 409 patients were included (ceftaroline = 67, daptomycin = 342). Ceftarolinepatients were older, less likely to be Black, more likely to have diabetes with complications, and had higher Charlson comorbidity scores. Median (interquartile range) time from admission to drug initiation was 1 (0-1) day for ceftaroline and 1 (1-3) day for daptomycin (p = 0.01). Unadjusted hospital readmission rates for ceftaroline and daptomycin, respectively, were: 30-day (25%/37%, p = 0.06), 60-day (27%/44%, p = 0.008), and 90-day (28%/46%, p = 0.01). Unadjusted mortality rates were: in-hospital (7%/12%, p = 0.4), 30-day (3%/9%, p = 0.1), 60-day (6%/12%, p = 0.2), and 90-day (7%/15%, p = 0.1). In multivariable models with all divergent baseline characteristics included as covariates, patients treated with ceftaroline were less likely to experience (OR, 95% CI): 30/60/90-day hospital readmission (0.54, 0.29-0.98; 0.42, 0.23-0.76; 0.42, 0.23-0.75) and 30/60/90-day mortality (0.23, 0.04-0.82; 0.34, 0.10-0.93; 0.34, 0.11-0.86). Conclusion: In patients with sepsis, ceftaroline was associated with fewer hospital readmissions and lower mortality as compared to daptomycin. Prospective investigations in larger, more generalized cohorts are needed to examine outcomes with specific MRSA therapies.
Authors: Tony T Ho; Jose Cadena; Lindsey M Childs; Miguel Gonzalez-Velez; James S Lewis Journal: J Antimicrob Chemother Date: 2012-02-06 Impact factor: 5.790
Authors: Jared A Silverman; Lawrence I Mortin; Andrew D G Vanpraagh; Tongchuan Li; Jeff Alder Journal: J Infect Dis Date: 2005-05-05 Impact factor: 5.226
Authors: Anthony M Casapao; Susan L Davis; Viktorija O Barr; Kenneth P Klinker; Debra A Goff; Katie E Barber; Keith S Kaye; Ryan P Mynatt; Leah M Molloy; Jason M Pogue; Michael J Rybak Journal: Antimicrob Agents Chemother Date: 2014-02-18 Impact factor: 5.191
Authors: George Sakoulas; Pamela A Moise; Anthony M Casapao; Poochit Nonejuie; Joshua Olson; Cheryl Y M Okumura; Michael J Rybak; Ravina Kullar; Abhay Dhand; Warren E Rose; Debra A Goff; Adam M Bressler; Yuman Lee; Joseph Pogliano; Scott Johns; Glenn W Kaatz; John R Ebright; Victor Nizet Journal: Clin Ther Date: 2014-07-10 Impact factor: 3.393
Authors: Pamela A Moise; Darren L Culshaw; Annie Wong-Beringer; Joyce Bensman; Kenneth C Lamp; Winter J Smith; Karri Bauer; Debra A Goff; Robert Adamson; Kimberly Leuthner; Michael D Virata; James A McKinnell; Saira B Chaudhry; Romic Eskandarian; Thomas Lodise; Katherine Reyes; Marcus J Zervos Journal: Clin Ther Date: 2015-11-14 Impact factor: 3.393